** Amgen Inc AMGN.O down 2.6% to $283.41 ahead of Q1 results due after the closing bell

** The biotech company is expected to post adj EPS of $4.30 on revenue of $8.06 bln, per LSEG data, vs yr-ago results of $3.96 per share in earnings and $7.45 bln in revenue

** AMGN has met or beat EPS estimate in seven of past eight qtrs, with most recent miss in Q2 2024

** Investors will look for any comments related to the potential effect of the Trump administration's tariffs on pharmaceuticals

** Of the 33 analysts that cover AMGN, the breakdown of recommendations is 16 "strong buy" or "buy," 14 "hold" and 3 "sell" or "strong sell" ratings

** Median price target of $329 is up from $316 on Feb 1

** With moves on Thurs, AMGN shares up ~9% YTD vs ~4% drop in the Dow Industrials .DJI

** AMGN options imply a 4.5% swing for the shares, in either direction, by Fri; that is just below the 5% move the stock has logged on the day after results over the last 8-qtrs, according to Trade Alert

(Reporting by Chuck Mikolajczak, additional reporting by Saqib Ahmed)

((charles.mikolajczak@tr.com; @chuckmik.bsky.social))